Tesamorelin

Tesamorelin (brand name Egrifta) is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) that is FDA-approved for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is the only GHRH analog with a full FDA approval backed by phase 3 clinical trial data. The drug consists of the full 44-amino-acid sequence of human GHRH(1-44) fused to a trans-2-hexenoic acid moiety at the N-terminus that confers stability against enzymatic degradation, extending its plasma half-life to approximately 26-38 minutes — meaningfully longer than native GHRH.

HIV-associated lipodystrophy is characterized by pathological accumulation of visceral adipose tissue (VAT), often alongside peripheral fat loss (lipoatrophy), and is driven in part by antiretroviral therapy and HIV-associated relative GH deficiency. Tesamorelin restores physiological pulsatile GH secretion and the downstream rise in IGF-1, which promotes lipolysis preferentially in visceral depots. The pivotal phase 3 trials demonstrated significant and durable reductions in VAT on computed tomography (CT) compared to placebo, leading to FDA approval in 2010.

Off-label, tesamorelin is explored for visceral fat reduction in non-HIV populations (obesity, GH deficiency), improvement of liver fat (NAFLD/MASLD), and potential metabolic and cognitive benefits via GH/IGF-1 normalization. Compounded tesamorelin is available through telehealth providers in the United States but carries less standardization than the branded Egrifta formulation. Evidence grade: **A** for HIV-associated lipodystrophy (FDA-approved, multiple phase 3 RCTs); **B** for off-label metabolic indications (mechanistically supported, smaller or non-primary-endpoint data).

Tesamorelin binds GHRH receptors (GHRHR) on anterior pituitary somatotrophs, activating adenylyl cyclase and cAMP-dependent signaling that drives pulsatile GH secretion. Unlike synthetic GH (somatropin), tesamorelin does not bypass the hypothalamic-pituitary axis — it amplifies the body\'s own GH pulses, preserving feedback regulation via somatostatin and endogenous IGF-1. This means GH levels rise within physiological range rather than to the supraphysiological levels seen with exogenous GH injection, which may explain the relatively favorable safety profile in clinical trials [1].

Elevated GH directly stimulates hepatic production of IGF-1. Both GH and IGF-1 activate hormone-sensitive lipase and suppress lipoprotein lipase in adipocytes, promoting lipolysis. Visceral adipose tissue appears to be more sensitive to GH-driven lipolysis than subcutaneous fat, accounting for the preferential VAT reduction seen in trials. Tesamorelin also reduces liver fat independent of changes in VAT volume, possibly via direct hepatic GH receptor signaling [6], and has been shown to improve fat tissue quality (intramyocellular and hepatic lipid content) beyond simple fat-volume metrics [4].

The pivotal evidence for tesamorelin comes from two independent phase 3 RCTs and a subsequent pooled analysis. Falutz et al. (NEJM, 2007) enrolled 412 HIV-infected patients with abdominal fat accumulation in a 26-week, randomized, double-blind, placebo-controlled trial [1]. Patients receiving tesamorelin 2 mg daily subcutaneously achieved a mean VAT reduction of approximately 17.8% on CT versus a 3.2% reduction in the placebo group — a statistically significant and clinically meaningful difference. IGF-1 rose approximately 78% in the tesamorelin arm. Patients and their physicians rated abdominal appearance as significantly improved. Glycated hemoglobin (HbA1c) did not differ significantly between arms at 26 weeks.

Falutz et al. (JAIDS, 2010) reported a follow-up RCT with an open-label safety extension through 52 weeks [2]. VAT continued to decrease through 26 weeks, and patients who switched from tesamorelin to placebo during the extension phase regained visceral fat — demonstrating that the drug\'s effect requires continued use. The pooled phase 3 analysis (Falutz et al., J Clin Endocrinol Metab, 2010) confirmed the primary efficacy results across two independent trials and provided the most robust safety database [3]. A 2026 meta-analysis of all available RCTs (Badran et al.) confirmed significant VAT reduction, hepatic fat improvement, and a favorable metabolic profile with no significant increase in diabetes incidence [5].

Beyond the HIV indication, tesamorelin has shown promise in improving hepatic fat in HIV-infected and non-HIV populations, reducing intrahepatic lipid and FGF-21 levels in a small trial focused on GH augmentation [6]. Lake et al. (AIDS, 2021) demonstrated that tesamorelin improved visceral fat quality (assessed by CT Hounsfield unit density, a marker of adipose tissue inflammation and metabolic dysfunction) independent of the quantity of fat lost [4] — suggesting benefits beyond simple VAT volume reduction. Off-label use in non-HIV populations with excess visceral fat or relative GH deficiency is mechanistically plausible but has not yet been tested in adequately powered RCTs.

A separate line of research explored GHRH agonists for cognitive outcomes. Baker et al. (Arch Neurol, 2012) randomized 152 older adults with or without mild cognitive impairment to GHRH therapy or placebo for 20 weeks; GHRH improved executive function and verbal memory, consistent with IGF-1\'s role in hippocampal neuroplasticity [7]. This study used a different GHRH preparation but is relevant to tesamorelin\'s mechanism, as both agents act on GHRHR. Cognitive efficacy for tesamorelin specifically has not been established in a dedicated trial.

The FDA-approved dose of tesamorelin for HIV-associated lipodystrophy is 2 mg administered as a subcutaneous injection once daily. The standard injection site is the abdomen; sites should be rotated to minimize local reactions. Tesamorelin should be reconstituted per manufacturer instructions and used immediately after preparation or refrigerated briefly. Clinical response is typically assessed by CT or DXA measurement of visceral fat at 26 weeks; if no meaningful response is seen, discontinuation should be considered.

Off-label providers sometimes use lower doses (1 mg daily) or alternate-day protocols to manage cost and minimize IGF-1 elevation. There are no published dose-finding studies in non-HIV populations to guide off-label protocols. IGF-1 monitoring is recommended during therapy to keep levels within the age-adjusted normal range. Therapy is typically cycled (e.g., 3-6 months on, 1-2 months off) in off-label use, though evidence for this approach is anecdotal. Tesamorelin is not indicated in pregnancy or during active malignancy.

In the phase 3 trials, tesamorelin was generally well tolerated [[cite:1],[cite:3]]. The most common adverse events were injection-site reactions (erythema, pruritus, pain) in up to 25% of subjects. Peripheral edema and arthralgia were reported at low rates. Tesamorelin caused a modest, transient rise in fasting glucose and insulin in some patients, consistent with GH\'s counter-regulatory effect on insulin; however, HbA1c differences versus placebo were not statistically significant at 26 weeks, and the 2026 meta-analysis found no significant increase in incident diabetes [5]. IGF-1 levels rose substantially (~78%), which is expected but warrants monitoring in those at risk for IGF-1-sensitive conditions.

Tesamorelin is contraindicated in patients with active malignancy, pituitary tumor or history of pituitary surgery, pregnancy (Category X under old FDA classification), or hypersensitivity to GHRH or any component. Unlike exogenous GH (somatropin), which is associated with acromegaly at supraphysiological doses, tesamorelin\'s mechanism of amplifying endogenous pulsatile GH preserves the natural feedback axis, theoretically limiting GH overshoot. Long-term safety beyond 52 weeks in HIV populations and beyond any duration in non-HIV populations has not been systematically studied. Compounded tesamorelin sourced outside licensed pharmacies carries additional risks of contamination or mislabeled potency.